Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced cholestasis.

Cynthia Levy1, Keith D Lindor

  • 1Division of Gastroenterology and Hepatology, W 19A, Mayo Clinic and Foundation, 200 1st Street, SW, Rochester, MN 55905, USA.

Clinics in Liver Disease
|July 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accessibility and harmonization of biochemical tests for diagnosis and monitoring of Porphyrias in the United States: Recommendations by members of the American Porphyrias Expert Collaborative (APEX).

Molecular genetics and metabolism·2026
Same author

Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective.

The American journal of gastroenterology·2026
Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026
Same author

Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year Analysis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Alimentary pharmacology & therapeutics·2026
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Drug-induced cholestasis requires high suspicion for diagnosis. Promptly stopping the causative drug is key for treatment, though some medications offer limited symptomatic relief.

Area of Science:

  • Hepatology
  • Clinical Pharmacology

Background:

  • Drug-induced cholestasis is a frequent clinical issue.
  • It is associated with diverse drug classes and can present with varying hepatitis severity.

Purpose of the Study:

  • To highlight the diagnostic and management principles of drug-induced cholestasis.
  • To review therapeutic options and patient prognosis.

Main Methods:

  • Literature review of drug-induced cholestasis.
  • Analysis of clinical presentations, diagnostic challenges, and treatment outcomes.

Main Results:

  • Diagnosis relies on a high index of suspicion.
  • Discontinuation of the offending agent is the primary treatment.
  • Symptomatic treatments for pruritus show limited efficacy.

Related Experiment Videos

Conclusions:

  • Early recognition and drug withdrawal are crucial for favorable outcomes.
  • While prognosis is generally good, prolonged cases can lead to vanishing bile duct syndrome or rare liver failure.